Keywords: Biogen Idec, BG-12, Phase III, Multiple sclerosis
Biogen Idec rises on strong Ph III data with oral MS drug BG-12
Article | 12 April 2011
US drugmaker Biogen Idec (Nasdaq: BIIB) shares closed up 7.2% at $78.55 6.4% in heavy trading yesterday, after announcing positive top-line results from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
